Use of clazakizumab to desensitize hla-sensitized patients and improve renal transplantation

Clazakizumab addresses the limitations of current desensitization protocols by reducing donor-specific antibodies in HLA-sensitized patients, enhancing transplant success through sustained antibody reduction and preventing rejection.

JP2024161505APending Publication Date: 2024-11-19CEDARS SINAI MEDICAL CENT
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
JP2024135834
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-06-01
Filing Date
2024-08-16
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current desensitization protocols for HLA-sensitized patients in organ transplantation are ineffective in completely removing donor-specific antibodies, leading to acute rejection and chronic damage to allografts, with IVIG and rituximab causing false-positive test results and DSA rebound.

Method used

Administer clazakizumab, an IL-6-binding monoclonal antibody, either alone or in combination with IVIG and plasmapheresis, prior to and after transplantation to reduce donor-specific antibodies, using a regimen of multiple doses to achieve desensitization.

Benefits of technology

Clazakizumab effectively reduces donor-specific antibodies to undetectable levels, preventing acute rejection and maintaining graft function, with sustained antibody reduction up to six months post-transplant, thereby increasing engraftment rates and reducing antibody-mediated rejection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161505000001_ABST
    Figure 2024161505000001_ABST
Patent Text Reader

Abstract

To provide methods for desensitization of patients in need of organ transplant.SOLUTION: Human leukocyte antigen-sensitized patients awaiting incompatible kidney transplantation, who have been treated with clazakizumab, show reduced or eliminated levels of donor-specific antibodies and an improved transplantion rate. Clazakizumab and variants are provided for use in various embodiments of the methods. In some embodiments, clazakizumab or its variants are administered simultaneously or sequentially with intravenous immunoglobulin.SELECTED DRAWING: Figure 19
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 757,676, filed November 8, 2018, and U.S. Provisional Patent Application No. 62 / 855,988, filed June 1, 2019, each of which is incorporated by reference in its entirety.

[0002] The present invention relates to therapeutic and treatment methods for desensitization in sensitized patients and for the improvement of organ transplants. [Background technology]

[0003] All publications in this specification are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description contains information that may be useful in understanding the present invention. No admission is made that any information provided herein is prior art or relevant to the presently claimed invention, or that any publications referenced, expressly or implicitly, are prior art.

[0004] The causes of accelerating renal allograft attrition are multifactorial. Recent data have overturned the long-held view that calcineurin inhibitor (CNI) toxicity was the primary cause of most chronic allograft failures. It is now recognized that alloimmune reactions are responsible for the majority of renal allograft failures, totaling 5,000 cases per year in the United States. The costs associated with failed allografts represent a substantial economic burden to the healthcare system, as well as a reduced life expectancy and quality of life for patients. Patients returning to the transplant list after allograft failure are now the fourth largest category of new patient listings in the United States. These patients represent a major challenge for transplant centers, as they are highly human leukocyte antigen (HLA) sensitized and unlikely to receive another transplant without significant desensitization. Currently, there are no FDA-approved drugs in this category. The development of novel therapeutic approaches to reduce allo-sensitization and improve engraftment rates is of paramount importance. Today, this is one of the most important goals of transplant medicine.

[0005] HLA molecules are polymorphic. Each HLA molecule expresses polymorphic private epitopes and numerous public determinants that represent epitopes shared by multiple HLA molecules. Immunization after previous transplantation, blood transfusion, or pregnancy can lead to the development of HLA-specific antibodies. An important responsibility of the immunogenetics laboratory is to identify and analyze HLA-specific antibodies present in the serum of patients before and after transplantation. Knowledge of the specificity of alloantibodies can help predict the likelihood of finding a compatible donor for crossmatching, can help avoid transplantation with donors carrying HLA antigens to which the patient is sensitized, can help select the optimal crossmatch method, and / or can help avoid false-positive crossmatches with donors by excluding clinically irrelevant antibodies.

[0006] Antibodies against HLA antigens have a profound effect in mediating allograft injury and loss and remain a persistent and often stubborn obstacle to successful engraftment for the thousands of patients on kidney transplant lists worldwide. Preformed or de novo donor-specific antibodies (DSA) activate complement, induce endothelial cell proliferation, and promote antibody-dependent cellular proliferation. DSA mediates cytotoxicity (ADCC) in allografts, which causes the recipient to become highly HLA sensitized and suffer from persistent immune attack on the allograft, leading to the development of interstitial fibrosis, tubular atrophy (IF / TA), and allograft dysfunction and loss. Patients who return to dialysis often have little hope of receiving a second transplant and are at higher risk of dying during dialysis. DSA is also known to promote atherosclerosis in allografts, thus hastening vascular death in the kidney.

[0007] To increase kidney transplantation rates in sensitized patients, novel protocols of HLA desensitization have emerged. This approach requires the application of intravenous immunoglobulin (IVIG), rituximab, and plasma exchange (plasmapheresis, PLEX). There is growing interest in developing novel immunomodulatory agents that are less expensive and more convenient to use to ameliorate antibody reduction during transplantation.

[0008] Existing IVIG-related treatments mainly have two desensitization regimens, namely low-dose intravenous immunoglobulin with plasma exchange (IVIG / PLEX) and high-dose IVIG (HD-IVIG). IVIG / PLEX has been used successfully in ABO-incompatible and positive crossmatched (+CMX) living donor kidney transplants, and HD-IVIG has been used to desensitize both living donor +CMS recipients on the waiting list and highly HLA-sensitized post-mortem donor (HS-DD) recipients. HD-IVIG (2g / kg) in a multiple-dose regimen is considered a reasonable approach for desensitization. Rituximab, a B-cell depleting agent, is often used in combination with HD-IVIG and IVIG / PLEX protocols. It has been shown that rituximab in IVIG / rituximab protocols can modify alloreactive B cells to prevent rebound DSA.

[0009] The main problem with existing desensitization regimens lies in the interpretation of CMX and DSA results when IVIG and rituximab are present in the test serum. IVIG administered at a dose of 2 mg / kg (up to 140 grams) is likely to interfere with LUMINEX testing for DSA, resulting in false-positive results. This could theoretically be avoided by waiting at least one month after IVIG administration before performing LUMINEX single antigen bead (LSA) testing, as IVIG has a half-life of 30-40 days. Rituximab does not interfere with the LSA testing platform, but does produce "false-positive" CDC+ and flow cytometry crossmatch (FCMX)-positive B-cell crossmatches that may be incorrectly interpreted as due to DSA. Pronase treatment of B cells prior to FCMX and CDC testing generally reduces the efficacy of rituximab, but this cannot always be relied upon.

[0010] Alloantibodies are a major impediment to access and success of life-saving organ transplantation. Despite advances in desensitization, designing efficient and effective means to remove pathogenic anti-HLA antibodies remains a significant medical challenge. Existing desensitization protocols have many notable deficiencies. For example, current treatments are unable to substantially completely remove DSA before transplantation, resulting in a risk of acute rejection. There is also a risk of rebound DSA formation after transplantation, with acute and chronic damage to the allograft. Some of the current protocols, particularly those that use complement inhibitors to prevent chronic antibody-mediated rejection (cABMR), still fail to achieve the desired outcome. Thus, there is an unmet medical need to improve the ability to reduce or remove existing HLA antibodies to a level that would enable patients to receive life-saving organ transplants. Summary of the Invention [Problem to be solved by the invention]

[0011] Therefore, the object of the present invention is to improve the solid organ transplantation rates in HLA-sensitized subjects by using already existing The object of the present invention is to provide a composition for use in combination with, as an improvement to, or as a replacement for existing standard desensitization treatments. [Means for solving the problem]

[0012] The following embodiments and aspects thereof have been described and illustrated in conjunction with compositions and methods that are meant to be exemplary and illustrative rather than limiting in scope.

[0013] Methods are provided for reducing donor-specific antibodies in and / or desensitizing human subjects sensitized to human leukocyte antigens (HLA). The methods include administering to a subject a polypeptide comprising clazakizumab; an IL-6-binding fragment of clazakizumab; or a VDG comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2, or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L and administering to the subject an effective amount of a polypeptide having a polypeptide sequence and a polypeptide sequence comprising the polypeptide sequence and a polypeptide sequence of the ...

[0014] In one embodiment, the clazakizumab, the IL-6 binding fragment of clazakizumab, or the polypeptide disclosed herein is administered before transplantation. In another embodiment, the clazakizumab, the IL-6 binding fragment of clazakizumab, or the polypeptide is administered after transplantation. In yet another embodiment, it is provided that the clazakizumab, the IL-6 binding fragment of clazakizumab, or the polypeptide is administered both before and after transplantation.

[0015] In some embodiments of the method of the present disclosure, in addition to administering the clazakizumab, the IL-6 binding fragment of clazakizumab, or the polypeptide disclosed herein, standard of care treatment is provided, including intravenous immunoglobulin (IVIG) administration, rituximab administration, plasma exchange, or a combination thereof.In one aspect, the standard of care treatment is administered before the clazakizumab, the IL-6 binding fragment of clazakizumab, or the polypeptide.In another aspect, the standard of care treatment is administered simultaneously with or after the administration of the clazakizumab, the IL-6 binding fragment of clazakizumab, or the polypeptide.

[0016] In one embodiment, a method is provided for desensitizing an HLA-sensitized human patient awaiting renal transplant, the method comprising administering an effective amount of clazakizumab, an IL-6-binding fragment of clazakizumab, or a polypeptide disclosed herein. In another embodiment, a method is provided for desensitizing an HLA-sensitized human patient awaiting renal transplant, the method comprising administering an effective amount of (1) clazakizumab, an IL-6-binding fragment of clazakizumab, or a polypeptide disclosed herein, (2) a standard of care treatment, such as IVIG, plasma exchange, rituximab, or a combination thereof, and optionally (3) an anti-infective agent.

[0017] In other embodiments, it is provided that one or more of the methods are for desensitizing HLA-sensitized human patients for other solid organ transplants, including heart, liver, lung, pancreas, or intestine.

[0018] In one embodiment, clazakizumab, an IL-6 binding fragment thereof, or a polypeptide is administered subcutaneously at an average dose of about 1-5, 5-10, 10-20, or 20-30 mg / administration for 1, 2, 3, 4, 5, or 6 times prior to transplantation and 4, 5, 6, 7, 8, 9, 10, 11, or 12 times after transplantation, and the subject has a reduced amount of donor-specific antibodies after treatment compared to before treatment. In various aspects, the clazakizumab, antigen-binding fragment thereof, or polypeptide disclosed herein after transplantation is administered subcutaneously for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times after transplantation. It is provided that the subject is administered a dose of clazakizumab, IVIG, and plasma exchange before transplantation, followed by 6 doses or 12 doses of clazakizumab after transplantation. In various embodiments, the disclosed method comprises administering clazakizumab, its antigen-binding fragment, or polypeptide disclosed herein to a human subject who is HLA-sensitized and needs or has undergone a kidney transplant, and the subject's creatinine level is reduced after treatment compared to before treatment, there is no or undetectable presence of donor-specific antibodies, and / or the subject has no detectable symptoms or evidence of the onset of antibody-mediated rejection (e.g., no deterioration of allograft function as measured by serum creatinine and estimated glomerular filtration rate; no detectable evidence of capillaritis, inflammation, or complement (C4d) deposition). In further aspects of the embodiments, the subject's creatinine levels are reduced and maintained at the reduced levels for 1 month, 2 months, 3 months, 4 months, 5 months, or longer, concurrently with or following administration of clazakizumab, an antigen-binding fragment thereof, or a polypeptide disclosed herein.

[0019] Also provided is a pharmaceutical composition for use in administration to an HLA-sensitized subject to desensitize the subject and increase engraftment rates, comprising clazakizumab, an IL-6-binding fragment of clazakizumab, or a polypeptide disclosed herein, and a pharmaceutically acceptable excipient (e.g., amino acids, sorbitol, and a diluent).

[0020] In various embodiments, there is provided the use of clazakizumab in patients who are HLA sensitized and awaiting a mismatched kidney transplant, where DSA, complement dependent cytotoxicity (CDC), and / or antibody dependent cellular cytotoxicity (ADCC) are reduced or eliminated (e.g., DSA is reduced or eliminated in serum). In some embodiments, patients treated with clazakizumab are suitable for transplant and are less likely to have an antibody response.

[0021] In some embodiments, it is provided that one or more of the methods of the present disclosure further comprise selecting a mammalian (e.g., human) patient who is HLA sensitized and awaiting a mismatched deceased donor (DD) or living donor (LD) kidney transplant.

[0022] Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, various features of embodiments of the invention.

[0023] Exemplary embodiments are illustrated in the referenced drawings: It is intended that the embodiments and drawings disclosed herein are to be considered illustrative and not restrictive. [Brief description of the drawings]

[0024] [Figure 1] Shown is the DSA profile in the study for subject "ClazaDES01," a 50 year old African American female with a history of End Stage Renal Disease (ESRD) secondary to biopsy-proven focal segmental glomerulosclerosis (FSGS), on dialysis since November 2008 (i.e., approximately 10 year waiting period for B+ blood type), with a calculated panel reactive antibody (cPRA) of 58%. The patient's sensitizing events included 4 pregnancies and blood transfusions. [Diagram 2]DSA profiles for subject "ClazaDES05" before and after transplantation are shown (median fluorescence intensity, MFI). Subject "ClazaDES05" is a 36-year-old female with a history of ESRD secondary to IgA nephropathy, on dialysis since June 2008 (i.e., approximately 10 years waiting period for A+ blood type), with a cPRA of 100%. The patient's sensitization events included previous transplants and blood transfusions. Subject "ClazaDES05" received a kidney transplant from a deceased donor after four doses of clazakizumab. The patient had two types of DSA (class I and II) before and after transplantation. DSA intensity decreased from MFI>12,500 MFI at transplant to MFI=0 10 days after transplantation for class I, and from MFI>17,500 at transplant to MFI>3250 10 days after transplantation for class II. Per study protocol, patients continued monthly clazakizumab for 6 months after transplantation. [Figure 3A] Figure 1 shows overall C-reactive protein levels in the clazakizumab desensitization study. Overall, C-reactive protein (CRP) decreased from baseline to near zero at 2 months. The number of subjects included in the analysis at each time point is indicated in parentheses. [Figure 3B] Individual C-reactive protein levels in the clazakizumab desensitization study from baseline to month 7 are shown. [Figure 4] Shown is the sum of MFI over time from before plasma exchange (PLEX) (pre-PLEX) to the 5th dose of clazadesumab (N=9). Typically, MFI tends to recover approximately 1-3 months after completion of PLEX / IVIG. Here, with monthly clazadesumab injections, the sum of MFI continued to decrease over time when compared to pre-PLEX. To date, three patients have undergone transplantation. Patients ClazaDES01 and ClazaDES03 underwent transplantation after the 1st dose of clazadesumab. Patient ClazaDES05 underwent transplantation after the 4th dose of clazadesumab. [Diagram 5]An exemplary method for desensitizing HLA-sensitized patients prior to kidney transplantation is outlined. Patients receive up to six doses of clazakizumab while monitoring anti-HLA antibodies (DSA levels), Treg cells, and plasmablasts at selected time points during the study. For example, DSA levels are collected at all time points, including day 0, except day 7. C-reactive protein (CRP) and quantitative immunoglobulin (QIC) amounts are collected at all time points, including baseline (day -15), except day 0. In addition, at baseline (day -15) and day 180, the following are collected: CD4+ / CD25+ / Fox P3+ / CD127 low cell counts (Tregs); Th17+ cell counts; and CD19+ / CD38+ / CD27+ / IL-6+ (plasmablasts). For subjects who undergo transplantation before day 180, specialized testing is performed prior to transplantation. For subjects undergoing transplant prior to 180 days, specialized testing will be performed prior to transplant on transplant day 0. For maintenance, the standard regimen includes tacrolimus, mycophenolate mofetil, and steroids. [Figure 6]An exemplary method for post-transplant prevention and / or treatment to reduce donor-specific antibodies is outlined. In the embodiment after pre-transplant treatment illustrated in FIG. 5, IVIG and clazakizumab are administered after transplant (in FIG. 6, the transplant date is day 0). DSA levels are monitored on days 0, 90, and 180, and also on day 270 for those receiving the second dose. CRP and QIG levels are collected on days 0, 30, 60, 90, 120, 150, and 180, and also on days 240 and 300 for those receiving the second dose. At day 180 (approximately 6 months) after transplant, the following levels are collected: CD4+ / CD25+ / Fox P3+ / CD127 low cell counts (Tregs); Th17+ cell counts; and CD19+ / CD38+ / CD27+ / IL-6+ (plasmablasts). Viral PCT testing (for cytomegalovirus, Epstein-Barr virus, polyomavirus, BK virus, JC virus, and parvovirus B19) will be performed on days 30, 90, 180, and if the patient is receiving a second dose, on days 270 and 330. For maintenance, the standard regimen includes tacrolimus, mycophenolate mofetil, and steroids. "Additional plans" include that if the patient shows stability or improvement on a) 6M protocol biopsy Banff 2015 read; b) glomerular filtration rate (GFR); c) DSA, the patient will continue monthly clazakizumab for six more doses (approximately days 180, 210, 240, 270, 300, and 330). [Figure 7] 1 shows a timeline of treatment for patient "ClazaDES03" in the example study, and his creatinine levels (mg / dL) from pre-treatment to post-treatment. [Figure 8] 1 shows a kidney transplant biopsy from patient "ClazaDES03" approximately 2 months after transplant, including tubular injury, arteriosclerosis, and highly focal tubulitis. [Figure 9]Kidney transplant biopsy from patient "ClazaDES03" approximately 6 months post-transplant, showing acute tubular necrosis, rare isometric vacuoles, and mild tubulointerstitial inflammation. [Figure 10] Figures 10A-B show flow panel reactive antibody testing (flow-PRA) class I / class II before desensitization and after transplantation (post-Tx), respectively. [Figure 11] HLA class I & II antibodies and total levels of various markers before desensitization and at last follow-up (F / U) approximately 6-12 months after transplantation for subject DES03 who received clazakizumab. No DSA was detected at or after transplantation. [Figure 12-1] Figures 12A-12C show HLA class I & class II antibodies and total levels of various markers pre-desensitization and post-transplant for subject DES05 who received clazakizumab. [Figure 12-2] Continued from Figure 12-1. [Figure 13-1] Figures 13A-13C show HLA class I & class II antibodies and total levels of various markers pre-desensitization and post-transplant for subject DES07 who received clazakizumab. [Figure 13-2] Continued from Figure 13-1. [Figure 14] Figure 1 shows HLA class I & class II antibodies and total amount of various markers before desensitization and after clazakizumab for subject DES02 (non-transplanted). [Figure 15] 1 shows HLA class I & class II antibodies and total amount of various markers before desensitization and after clazakizumab for subject DES09 (non-transplanted). [Figure 16] HLA class I & class II antibodies before and after clazakizumab for all study patients (N=10) are shown. [Figure 17-1] Figures 17A-C show HLA class I antibodies (Figure 17A), class II antibodies (Figure 17B) before and after clazakizumab in transplanted patients (N=8) (compared together in Figure 17C). [Figure 17-2] Continued from Figure 17-1. [Figure 18] DSA for individual patients is shown for class I & class II before desensitization, at transplant, and after transplant (N=8). [Figure 19] Mean DSA MFI is shown for class I & class II before desensitization, at implantation, & after implantation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] All references cited herein are incorporated by reference in their entirety as if fully set forth. Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 3 rd ed., Revised, J. Wiley & Sons (New York, NY 2006); March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 7 th ed., J. Wiley & Sons (New York, NY 2013); and Sambrook and Russel, Molecular Cloning: A Laboratory Manual 4 th ed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY 2012), provides those of skill in the art with a general guide to many of the terms used in this application. For reference on how to prepare antibodies, see D. Lane, Antibodies: A Laboratory Guide to Antibodies. tory Manual 2 nd ed.(Cold Spring Harbor Press,Cold Spring Harbor NY, 2013);Kohler and Milstein, (1976) Eur. J. Immunol. 6:511; Queen et al. U.S. Pat. No. 5,585,089; and Riechmann et al., Nature 332:323 (1988); U.S. Pat. No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); Ward et al., Nature 334:544-54 (1989); Tomlinson I. and Holliger P. (2000) Methods Enzymol, 326, 461-479; Holliger See, P. (2005) Nat. Biotechnol. Sep;23(9):1126-36).

[0026] One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

[0027] The term "transplant rate" generally refers to the number of patients who receive transplants for every 100 patients on the waiting list during a year. In some embodiments, the transplant rate is a measure of how frequently patients on a program's waiting list receive transplants. To make the figures easier to compare, in some embodiments, the rate is stated as "per 100 patients / year," which means that the rate is normalized to the number of patients who would receive transplants if there were 100 patients on the list over a year. For example, a transplant rate of 5 cases / 100 patients / year means that 5 transplants are performed for every 100 patients on the list over a year. Because this is a normalized rate, the number may include a decimal, such as 5.1 cases / 100 patients / year. This means that slightly more than 5 patients are expected to receive transplants for every 100 patients on the list over a year.

[0028] A positive crossmatch (+CMX) indicates the presence of donor-specific alloantibodies (DSA) in the serum of the potential recipient and is often associated with a graft loss rate of over 80%.

[0029] "HLA-sensitized (HS) patients" in the example test refer to patients on the United Network for Organ Sharing (UNOS) waiting list waiting for a kidney transplant, who have a calculated panel reactive antibody (cPRA) or a cross-match mismatched donor probability of 50% or more, and in various embodiments, also have a demonstrable DSA using LUMINEX bead technology, and also have a history of sensitization events (e.g., previous transplants, transfusions, and / or pregnancies). The presence of HLA-specific antibodies can be determined by testing the patient's serum against cells from a panel of HLA-typed donors or against solubilized HLA antigens attached to a solid support. In general, HLA-sensitized patients refer to patients with cPRA of 10%, 20%, 30%, 40%, or 50% or more.

[0030] "Subject" means a human or an animal. Typically, the animal is a vertebrate such as a primate, rodent, domestic animal, or game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, such as rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic and game animals include cattle; horses, pigs, deer, bison, buffalo, feline species (e.g., domestic cats), and canine species (e.g., dogs, foxes, wolves). The terms "patient", "individual" and "subject" are used interchangeably herein. In an embodiment, the subject is an animal. The animal may be, but is not limited to, a human, non-human primate, mouse, rat, dog, cat, horse, or cow. In addition, the methods described herein may be used to treat domestic animals and / or pets.

[0031] The terms "treat", "treatment", "treating" or "amelioration" refer to therapeutic treatment, the purpose of which is to reverse, alleviate, ameliorate, inhibit, slow or stop the progression or severity of a condition associated with a disease or disorder. The term "treat" includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder (e.g., weight loss or muscle loss due to cancer cachexia). A treatment is generally "effective" if one or more symptoms or clinical markers are reduced. Alternatively, a treatment is "effective" if the progression of a disease is inhibited or stopped. That is, "treatment" includes not only improvement of symptoms or markers, but also at least a halt in the slowing of progression or worsening of symptoms that would be expected in the absence of treatment. Beneficial or desired clinical outcomes include, but are not limited to, the relief of one or more symptoms, attenuation of the extent of the disease, stabilization of the disease state (i.e., not getting worse), delay or slowing of disease progression, amelioration or remission of the disease state, and detectable or undetectable (partial or total) remission. The term "treatment" of a disease also includes causing relief (including palliative treatment) of the symptoms or side effects of the disease.

[0032] The term "antibody" refers to an intact immunoglobulin or to a monoclonal or polyclonal antigen-binding fragment having an Fc (fragment crystallizable) region or an FcRn-binding fragment of the Fc region, referred to herein as an "Fc fragment" or "Fc domain". Antigen-binding fragments may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding fragments include, among others, Fab, Fab', F(ab')2, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), single-domain antibodies, chimeric antibodies, bispecific antibodies, and polypeptides that contain at least a portion of an immunoglobulin sufficient to confer specific binding of an antigen to the polypeptide. The Fc domain contains portions of the two heavy chains that contribute to two or three classes of antibodies. The Fc domain may be produced by recombinant DNA technology or by enzymatic (e.g., papain cleavage) or chemical cleavage of an intact antibody. The antibody may be a chimeric, humanized, or human antibody. The antibody may be an IgG1, IgG2, IgG3, or IgG4 antibody. In some embodiments, the antibodies herein have an Fc region that has been modified to alter at least one of effector function, half-life, proteolysis, or glycosylation.

[0033] The term "antibody fragment" refers to a protein fragment that contains only a portion of an intact antibody, generally including the antigen-binding site of the intact antibody, and thus retains the ability to bind to an antigen. Examples of antibody fragments encompassed by this definition include: (i) V L Domain, C L Domain, V H (ii) a Fab' fragment, which is a Fab fragment having one or more cysteine ​​residues at the C-terminus of the CH1 domain; (iii) a V H (iv) an Fd fragment having a V domain and a CH1 domain; H(v) a Fd' fragment having a V domain and a CH1 domain and also having one or more cysteine ​​residues at the C-terminus of the CH1 domain; L Domains and V H (vi) Fv fragment having a V domain; H (vii) an isolated CDR region; (viii) an F(ab')2 fragment, which is a bivalent fragment comprising two Fab' fragments linked by a disulfide bridge at the hinge region; (ix) single chain antibody molecules (e.g., single chain Fv, scFv); (x) light chain variable domains (V L ) connected to a heavy chain variable domain (V H (xi) a pair of tandem Fd segments (V) that together with complementary light chain polypeptides form a pair of antigen-binding regions; H -CH1-V H -CH1). The antibody or antibody fragment can be an scFv, a camelbody, a nanobody, an IgNAR (a single chain antibody derived from sharks), and a Fab fragment, a Fab' fragment, or a F(ab')2 fragment.

[0034] "Selectively binds" or "specifically binds" refers to the binding of an antibody or antibody fragment thereof as described herein to a target molecule. D 10 -5 M (10000nM) or less (e.g., 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12Specific binding refers to the ability of a polypeptide agent to bind to a target (e.g., a molecule present on a cell surface) with a specific binding affinity (M, or lower). Specific binding can be affected, for example, by the affinity and avidity of the polypeptide agent as well as the concentration of the polypeptide agent. One of skill in the art can determine appropriate conditions under which a polypeptide agent described herein selectively binds to a target using any appropriate method, such as titrating the polypeptide agent in an appropriate cell binding assay.

[0035] An "ineffective" treatment refers to less than 5% improvement in symptoms when the subject is administered the treatment. When specifically recited in the claims, an ineffective treatment may refer to less than 1%, 2%, 3%, 4%, 6%, 7%, 8%, 9%, or 10% improvement in symptoms.

[0036] "Adverse Event" An adverse event is any undesirable, unintended sign, symptom, or disease temporarily associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of causation. An adverse event may be any undesirable, unintended sign (abnormal laboratory findings), symptom, or disease temporarily associated with the use of a medicinal product, regardless of whether it is considered medicinal product-related. Surgery is not an adverse event, but a therapeutic measure for a condition requiring surgery. However, a condition requiring surgery is an adverse event if it occurs or is detected during the study in this example. A planned surgical procedure and the condition leading to this procedure are not adverse events if the condition is known before the start of the study treatment. In the latter case, the condition should be reported in the medical history.

[0037] A chronic condition is one that is present at the start of the study. A chronic condition that worsens during the study will be considered an adverse event. A chronic condition should be recorded as an adverse event if the frequency, intensity, or character of the condition worsens during the study.

[0038] "Abnormal Laboratory Findings" Any abnormal laboratory finding that meets any one of the following criteria should be considered an adverse event: Test results relate to concomitant symptoms; test results indicate the need for additional diagnostic testing or medical / surgical intervention; the test results lead to changes in study treatment administration (e.g., dose modification, interruption, or permanent discontinuation), or concomitant drug treatment (e.g., addition, interruption, or discontinuation), or any other change in concomitant medication or therapy; The test result leads to one of the outcomes included in the definition of a serious adverse event (Note: this would be reported as a serious adverse event); The test result will be considered an adverse event by the investigator.

[0039] Test results that are outside the reference range and do not meet one of the above criteria should not be reported as an adverse event. Repeated abnormal tests in the absence of the above conditions do not constitute an adverse event. Any abnormal test result determined to be an error does not need to be reported as an adverse event.

[0040] "Serious Adverse Event" A serious adverse event (SAE) is any untoward medical occurrence at any dose that is as follows: fatal (resulting in death); Life-threatening: If the adverse event occurred, the patient was at immediate risk of death from this adverse event. This does not include events that would have resulted in death if they occurred in a more severe form or continued; hospitalization is required or an extension of an existing hospitalization is required; resulting in persistent or significant impairment / incapacity; congenital anomalies / birth defects (in the case of children of patients exposed to the study treatment); A significant medical event that may not result in death, be life-threatening, or require hospitalization may be considered an SAE if, based on appropriate medical judgment, the event may endanger the subject and require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such events are allergic bronchospasm, blood dyscrasia, or convulsions that do not result in hospitalization, or intensive treatment in the emergency room or at home for the development of drug dependence or abuse.

[0041] Adverse events leading to hospitalization are considered serious. Any adverse event leading to initial admission to a health care facility or transfer to an acute / intensive care unit within a hospital is considered serious.

[0042] Hospitalization or prolonged hospitalization without an inciting clinical adverse event is not, in itself, a serious adverse event. Examples of events that are not considered serious adverse events include: (1) hospitalization for treatment of a pre-existing condition that is not related to the onset of a new adverse event or worsening of an existing condition, (2) social or administrative hospitalization, (3) any hospitalization that is not related to an inciting clinical adverse event, and (4) pre-planned procedures or surgeries should not be documented in the baseline documentation.

[0043] All adverse events require an assessment of severity by the investigator. Severity will be assessed using the following criteria: Mild: You notice some discomfort, but it doesn't interfere with your normal daily activities; Moderate: Discomfort sufficient to reduce or affect daily activities; and Severe: Inability to work or carry out daily activities.

[0044] To clarify the distinction between the terms "serious" and "severe," which are not synonymous, it is noted that the term "severe" is often used to describe the intensity (severity) of a particular event, such as a mild, moderate, or severe myocardial infarction. However, the event itself may be of relatively minor medical significance, such as a severe headache. This is not the same as "serious," which is based on patient / event outcome or behavior criteria that are typically associated with an event that poses a threat to the patient's life or function. Severity (not severity) serves as a guide for defining reporting obligations by regulatory authorities.

[0045] The assessment of causality is to determine whether there is a reasonable possibility that the study treatment caused or contributed to the adverse event. "Not related" explains that the temporal relationship to administration of the study treatment is missing or implausible, or evidence of another cause exists. "Unlikely related" explains that a causal relationship from the temporal relationship to administration of the study treatment is implausible, and other drugs, chemicals, or underlying conditions provide a plausible explanation. "Possibly related" explains that the temporal relationship to administration of the study treatment is implausible, and other drugs, chemicals, or underlying conditions provide a plausible explanation. "Definite association" describes a reasonable temporal sequence with administration of the study treatment, but the event could also be explained by a concomitant illness or other drug or chemical. Information regarding drug withdrawal may be missing or unclear. "Definite association" describes a plausible temporal association with administration of the study treatment, and the event could not be explained by a concomitant illness or other drug or chemical. The response to drug cessation (drug interruption) should be clinically plausible. The event must be confirmed pharmacologically or phenomenologically, using a full rechallenge procedure if necessary.

[0046] Interleukin-6 is a key mediator of inflammation and the development, maturation, and activation of T cells, B cells, and plasma cells. Excessive IL-6 production is associated with many human diseases characterized by excessive and unregulated antibody production and autoimmunity.

[0047] Methods of the present disclosure for desensitizing an HLA-sensitized subject, reducing the amount of donor-specific antibodies, and / or improving organ transplantation or transplant survival rates include administering to the subject an effective amount of clazakizumab; or an antibody or antigen-binding fragment thereof that shares at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence homology (identity) to clazakizumab or the complementarity determining regions (CDRs) of clazakizumab. Some embodiments provide that one or more of these methods further include administering an effective amount of IVIG or plasma exchange.

[0048] Clazakizumab is a glycosylated humanized monoclonal antibody (from a rabbit parent antibody) that targets interleukin-6. Clazakizumab peptide sequence and structure information is available from IMGT / mAb-db record #414. Peptide sequence analysis by BLAST reveals a perfect match with the peptide claimed in U.S. Pat. No. 8,062,864, the entirety of which is incorporated herein by reference. Further description of Clazakizumab and its variants is given in U.S. Pat. No. 7,935,340, the entirety of which is incorporated herein by reference, and this antibody or antibody fragment is suitable for the method disclosed herein for reducing or removing donor-specific antibodies in a subject who needs to receive or has received an allograft transplant. For example, this antibody can be used in combination with the antibody of SEQ ID NO: 1 (V H CDR1), SEQ ID NO: 2 or 3 (V H CDR2), and SEQ ID NO:4 (V H CDR1 polypeptide, CDR2 polypeptide, and CDR3 polypeptide, respectively, contained in each of the V H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. LThe anti-human IL-6 antibody comprises a variable heavy chain comprised in SEQ ID NO:8, 9, or 10, and a variable light chain comprised in SEQ ID NO:11 or 12. Asn-Tyr-Tyr-Val-Thr (SEQ ID NO: 1) Ile-Ile-Tyr-Gly-Ser-Asp-Glu-Thr-Ala-Tyr-Ala-Thr-Trp-Ala-Ile-Gly (SEQ ID NO: 2) Ile-Ile-Tyr-Gly-Ser-Asp-Glu-Thr-Ala-Tyr-Ala-Thr-Ser-Ala-Ile-Gly (SEQ ID NO: 3) Asp-Asp-Ser-Ser-Asp-Trp-Asp-Ala-Lys-Phe-Asn-Leu (SEQ ID NO: 4) Gln-Ala-Ser-Gln-Ser-Ile-Asn-Asn-Glu-Leu-Ser (SEQ ID NO: 5) Arg-Ala-Ser-Thr-Leu-Ala-Ser (SEQ ID NO: 6) Gln-Gln-Gly-Tyr-Ser-Leu-Arg-Asn-Ile-Asp-Asn-Ala (sequence number 7).

[0049] The variable heavy chain sequence is set forth below: SEQ ID NO:8-METGLRWLLLVAVLKGVQCQSLEESGGRLVTPGTPLTLTCTASGFSLSNY YVTWVRQAPGKGLEWIGIIYGSDETAYATWAIGRFTISKTSTTVDLKMTS LTAADTATYFCARDDSSDWDAKFNLWGQGTLVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVK.

[0050] The substituted variable heavy chain sequence is set forth below: SEQ ID NO:9-EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATWAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNL.

[0051] Another substituted variable heavy chain sequence is set forth below: SEQ ID NO:10-EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNL.

[0052] The variable light chain sequence is set forth below: SEQ ID NO:11-MDTRAPTQLLGLLLLWLPGARCAYDMTQTPASVSAAVGGTVTIKCQASQS INNELSWYQQKPGQRPKLLIYRASTLASGVSSRFKGSGSGTEFTLTISDL ECADAATYYCQQGYSLRNIDNAFGGGTEVVVKRTVAAPSVFIFPPSDEQL KSGTASVVCLLNN.

[0053] The substituted variable light chain sequence is set forth below: SEQ ID NO:12-IQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNA.

[0054] Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) antibody that binds to human IL-6 with an affinity of approximately 4 pM. Using multiple assays of signal transduction and cellular function in response to IL-6 alone (to measure classical signal transduction) and to the combination of IL-6 with sIL-6R (to measure trans-signal transduction), it has been demonstrated that clzakizumab is a potent and complete antagonist of IL-6-induced signal transduction as measured by phosphorylation of signal transducer and activator of transcription 3 (STAT3), as well as cellular functions such as cell proliferation, differentiation, activation, B cell production of immunoglobulins, and hepatocyte production of acute phase proteins (C-reactive protein [CRP] and fibrinogen). In addition, clzakizumab has been found to be a competitive antagonist of IL-6-induced cell proliferation.

[0055] Clazakizumab exhibits a broad range of immunomodulatory effects that may address destructive alloantibody responses to allografts and may be useful as a desensitizing agent to improve kidney transplant rates for highly HLA-sensitized patients. Clazakizumab has been widely evaluated in patients with rheumatoid arthritis, but has not yet been approved by the FDA for any condition. Since the introduction of IL-6 / IL-6R blockers, it has been reported that inhibition of the IL-6 / IL-6R pathway may be significantly beneficial in systemic lupus erythematosus (SLE) and other vasculitis disorders, with antibody-producing cells being reduced in treated patients. Currently, there is no information on clzakizumab in highly sensitized patients waiting for incompatible (HLAi) transplants or for the treatment of antibody-mediated rejection.

[0056] To date, studies of clazakizumab have been conducted in healthy subjects, as well as in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn's disease, graft-versus-host disease (GVHD), and tumors. Despite studies of clazakizumab in subjects, it has not been studied in subjects with highly sensitized patients undergoing kidney transplantation.

[0057] Various embodiments include one or more methods of reducing donor-specific antibodies in an HLA-sensitized subject, characterized in that the calculated panel reactive antibody (cPRA) or percentage of likely crossmatch mismatched donors is at least 10%, 20%, 30%, 40%, 50%, 60%, or 70%, comprising administering to the subject pre-kidney transplant, post-kidney transplant, or both pre- and post-kidney transplant, clazakizumab; an antigen-binding fragment thereof; or a VDG comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide comprised in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. LThe present invention provides a method for administering an effective amount of a polypeptide having a variable heavy chain of SEQ ID NO: 8, 9, or 10 and a variable light chain of SEQ ID NO: 11 or 12 to a subject who has been HLA-sensitized before or after receiving an allograft transplantation, to reduce or eliminate donor-specific antibodies in the subject after allograft transplantation. Some embodiments of the method further include selecting a subject with a calculated panel reactive antibody (cPRA) or a probability of crossmatch mismatched donor of at least 10%, 20%, 30%, 40%, 50%, 60%, or 70%. Some embodiments of the method further include performing a kidney transplant in the subject. Further embodiments of this method are characterized by a decrease in donor-specific antibodies following renal transplantation due to administration of clazakizumab or an antigen-binding fragment thereof; or characterized by an undetectable amount of donor-specific antibodies beginning at about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months following renal transplantation due to administration of clazakizumab or an antigen-binding fragment thereof.

[0058] Various embodiments relate to one or more methods of reducing donor-specific antibodies in an HLA-sensitized subject, comprising administering to a subject an effective amount of IVIG and (2) a polypeptide comprising: clazakizumab; an IL-6-binding fragment of clazakizumab; or a polypeptide comprising a CDR1 polypeptide contained in SEQ ID NO:1, a CDR2 polypeptide contained in SEQ ID NO:2 or 3, and a CDR3 polypeptide contained in SEQ ID NO:4. H A polypeptide having a CDR1 polypeptide included in SEQ ID NO:5, a CDR2 polypeptide included in SEQ ID NO:6, and a CDR3 polypeptide included in SEQ ID NO:7. L In one embodiment, the IVIG is administered to a subject in need thereof in combination with an effective amount of a polypeptide having a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide, the CDR1 polypeptide being included in SEQ ID NOs: 1, 2 or 3, and 4, respectively. Hand a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L In some embodiments, the HLA-sensitized subject is to receive a solid organ transplant, in one embodiment, the solid organ is from a cross-matched donor (i.e., the HLA-sensitized subject contains pre-transplant antibodies against HLA from the donor's organ), and in another embodiment, the solid organ is not from a positive cross-matched donor. In other embodiments, the one or more methods include administering an effective amount of IVIG and a polypeptide having a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide, each of which is comprised in SEQ ID NO: 1, 2, or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L In addition to administering an effective amount of a polypeptide having the polypeptide, the method further comprises performing a solid organ transplant.

[0059] Some embodiments of the method for reducing donor-specific antibodies in an HLA-sensitized subject include: (1) an effective amount of a combination of IVIG and clazakizumab; (2) an effective amount of a combination of IVIG and an IL-6 binding fragment of clazakizumab; or (3) an effective amount of a combination of IVIG and a VLK antibody comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L In one embodiment, the IVIG is administered in combination with an effective amount of a polypeptide combination having a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide, each of which is comprised in SEQ ID NOs: 1, 2 or 3, and 4.H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L In another embodiment, IVIG is further administered immediately prior to, during, or immediately after solid organ transplant in the subject.

[0060] Further embodiments include a method of reducing donor-specific antibodies in an HLA-sensitized subject, comprising administering to a subject an effective amount of a combination of IVIG, plasma exchange, and clazakizumab; (2) an effective amount of a combination of IVIG, plasma exchange, and an IL-6-binding fragment of clazakizumab; or (3) an effective amount of a combination of IVIG, plasma exchange, and a VDG comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L In one embodiment, the method includes administering an effective amount of a combination of a polypeptide having a polypeptide and a polypeptide comprising: clazakizumab; an IL-6 binding fragment of clazakizumab; or a polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide comprised in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L The polypeptide having the polypeptide of the present invention is administered prior to or simultaneously with the polypeptide having the polypeptide of the present invention.

[0061] In various embodiments, desensitization due to clazakizumab (1) led to engraftment in 8 of 10 patients in the example study, (2) led to a significant decrease in HLA specificity while cPRA did not change significantly, and (3) led to a decrease in DNA at and after transplantation with continued administration of an effective amount of clazakizumab.

[0062] In a further embodiment, anti-IL-6 treatment (e.g., administration of clazakizumab) has a significant effect on reducing the MFI level of class II / class II HLA antibodies, thereby increasing the engraftment rate of HLA-sensitized patients or increasing the chance or rate of transplant survival of individual HLA-sensitive patients. Anti-IL-6 mediates this through the reduction of plasma cells that produce IL-6 (anti-HLA). After treatment, anti-IL-6 therapy reduces or eliminates DSA levels and prevents de novo DSA generation. A further aspect also provides that patients receiving clazakizumab and solid organ transplants do not develop antibody-mediated rejection of the transplant.

[0063] Various embodiments provide that the method of the disclosure includes identifying an HLA-sensitized patient in need of a solid organ transplant, administering PLEX and IVIG and monthly doses of clazakizumab, performing the solid organ transplant (e.g., kidney transplant), administering induction therapy such as alemtuzumab and / or THYMOGLOBULIN (antithymocyte globulin), and administering immunosuppressive therapy such as tacrolimus, CELLCEPT (mycophenolate mofetil), and tapering prednisone. In one aspect, the engraftment rate of HLA-sensitized subjects after desensitization with clazakizumab and PLEX / IVIG is at least 50%. %, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. In another embodiment, the time to transplant following completion of pre-transplant desensitization with clazakizumab and PLEX / IVIG in HLA-sensitized subjects is 0 days to 1 week, 1 week to 1 month, 1 month to 3 months, 3 months to 6 months, 6 months to 1 year, 1 year to 2 years, or longer. In a further embodiment, previously HLA-sensitized subjects undergoing desensitization treatment with an effective amount of clazakizumab (optionally in combination with PLEX / IVIG) and receiving a renal allograft transplant are at least 95%, 90%, 85%, 80%, 75%, or 70% free of signs or symptoms of antibody-mediated rejection of the transplant. Further aspects of this method include that the subject does not have rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn's disease, graft-versus-host disease (GVHD), cancer, or a combination thereof. Further aspects of this method further include selecting a subject who does not have or has never had rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn's disease, graft-versus-host disease (GVHD), or cancer, is HLA-sensitive, and requires or has received a solid organ (e.g., kidney) transplant for the method of reducing and / or removing donor-specific antibodies.

[0064] Various embodiments provide that one or more of the disclosed methods further comprise performing one or more assays for the presence or absence of an infection associated with cytomegalovirus, Epstein-Barr virus, polyomavirus, BK virus, JC virus, parvovirus B19, or a combination thereof, on the subject before and / or after transplantation of the allograft. In other embodiments, one or more of the disclosed methods are characterized in that the subject does not have a detectable amount of an infection associated with cytomegalovirus, Epstein-Barr virus, polyomavirus, BK virus, JC virus, parvovirus B19, or a combination thereof, before and / or after transplantation of the allograft. Further embodiments provide that the subject in one or more of the disclosed post-transplant clazakizumab methods does not have chronic antibody-mediated rejection of the solid organ transplant or has been tested for the absence of evidence of chronic antibody-mediated rejection.

[0065] Various embodiments of methods for reducing or eliminating donor-specific antibodies in and / or desensitizing an HLA-sensitized subject in need of or undergoing allograft transplantation include administering, in one or more doses over time, an effective amount of clazakizumab, an IL-6 binding fragment of clazakizumab, a polypeptide comprising a variable heavy chain of SEQ ID NO:8, 9, or 10 and a variable light chain of SEQ ID NO:12 or 12, or a polypeptide comprising a variable heavy chain having CDR1 of SEQ ID NO:1, a CDR2 of SEQ ID NO:2 or 3, and a CDR3 of SEQ ID NO:4, and a variable light chain having CDR1 of SEQ ID NO:5, a CDR2 of SEQ ID NO:6, and a CDR3 of SEQ ID NO:7; (1) The subject has or has had preformed donor specific antibodies (DSA) prior to allograft transplantation and / or develops or has developed DSA following allograft transplantation, (2) the subject has a calculated panel reactive antibody of 50% or more, (3) the subject has a high intensity of donor specific antibodies, e.g., as determined by single antigen LUMINEX bead assay and expressed as a mean fluorescence intensity (MFI) of more than 9,000, 10,000, 11,000, 12,000, or higher for class I or class II, or (4) the subject has had one or more pregnancies, blood transfusions, and / or previous transplants. In one embodiment, the subject has one of the mentioned characteristics. In another embodiment, the subject has two of the mentioned characteristics. In yet another embodiment, the subject has three of the mentioned characteristics. In yet another embodiment, the subject has four of the mentioned characteristics.

[0066] Additional embodiments of the methods disclosed herein include one or more steps of immune monitoring before and / or after transplantation of the allograft. A method of reducing or eliminating donor-specific antibodies in a subject who had pre-formed DSA, 50% or greater cPRA, or high intensity DSA prior to transplantation of a graft, and who subsequently receives an allograft transplant (e.g., the allograft is HLA-mismatched to the subject), comprising: (i) administering an effective amount of clazakizumab, an IL-6-binding fragment of clazakizumab, or a polypeptide as disclosed above, in one or more doses; (ii) administering one or more doses individually (e.g., at 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 months, 35 months, 36 months, 37 months, 38 months, 39 months, 40 months, 41 months, 42 months, 43 months, 44 months, 45 months, 46 months, 47 months, 48 ​​months, 49 months, 50 months, 51 months, 52 months, 53 months, 54 months, 55 months, 56 months, 57 months, 58 months, 59 months, 60 months, 61 months, 62 months, 63 months, 64 months, 65 months, 66 months, 67 months, 68 months, 70 months, 71 months, 72 months, 73 months, 74 months, 75 months, 76 and / or (d) performing a post-transplant biopsy evaluation; (e.g., after one or more doses of clazakizumab, an IL-6-binding fragment of clazakizumab, or the polypeptide, over a period of time such as 1 month, 8 months, 9 months, 10 months, 11 months, 12 months, 15 months, 18 months, 24 months, or longer), (a) immune monitoring of the subject, such as assaying a blood sample from the subject to quantify Treg, Tfh, Th17, B cell, IL-6, CRP, plasma cell, plasmablast IgG levels, or a combination thereof; (b) performing a post-transplant biopsy evaluation; (c) measuring the glomerular filtration rate; and / or (d) measuring the amount of DSA in the subject;and, optionally, (iii) if (a) immune monitoring indicates improved immune responsiveness (e.g., characterized by lower levels of CRP, Treg, Tfh, Th17, B cell, IL-6, plasma cell, or plasmablast IgG compared to previous immune monitoring or baseline measurements at or before transplantation of the allograft, or comparable levels of CRP, Treg, Tfh, Th17, B cell, IL-6, plasma cell, or plasmablast IgG compared to healthy or desensitized subjects), (b) biopsy evaluation of the transplant indicates absence of cell- and antibody-mediated rejection, absence or reduced evidence of allograft dysfunction (e.g., as determined by C4d staining and transplant glomerulopathy using the Banff 2015 criteria), and / or absence of evidence of allograft dysfunction (e.g., as determined by C4d staining and transplant glomerulopathy using the Banff 2015 criteria), (c) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (d) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (e) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (e) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (f) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (g) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (h) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (i) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (i) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (ii) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody, and / or (i) the presence of a cytotoxic T cell antibody or cytotoxic T cell antibody if it shows improvement according to the 2015 criteria, (c) if the glomerular filtration rate is stable (e.g., if levels are similar or decreased compared to the last measurement or pre-transplant), or (d) if the amount of DSA is stable (e.g., if levels are similar or lower compared to the last measurement or pre-transplant), discontinue or limit further administration of clazakizumab, IL-6-binding fragment of clazakizumab, or polypeptide to no more than an additional 6 months; if immune monitoring indicates that immune reactivity, e.g., as described above, has not improved or the glomerular filtration rate or amount of DSA has not stabilized, continue administration of clazakizumab, IL-6-binding fragment of clazakizumab, or polypeptide or continue at an adjusted dosage; if biopsy evaluation of the transplant indicates the presence of cell-mediated and / or antibody-mediated rejection, administer standard of care treatment (e.g., IVIG, plasma exchange, or both) to treat the rejection. Optionally, steps (ii) and (iii) are repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, or as needed or until improvement, stabilization, or even cure is observed;

[0067] In some embodiments, if evidence of antibody-mediated rejection is observed, the subject is induced to treat antibody-mediated rejection.In some embodiments, after steps (i) and (ii), no further doses of clazakizumab, IL-6-binding fragment of clazakizumab, or polypeptide are administered for a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, and 3 months, etc. ("rest"), and after "rest", immune reactivity is monitored or a biopsy of the graft is evaluated, and depending on the results of the characterization in step (iii), the skilled artisan will discontinue or continue administration of clazakizumab, IL-6-binding fragment of clazakizumab, or polypeptide to further reduce or eliminate DSA in this subject.

[0068] Dosage In one embodiment, the reduction of donor-specific antibodies and HL in a subject (e.g., a human subject) is A method for A desensitization includes administering an effective amount of clazakizumab or an antigen-binding fragment of clazakizumab (e.g., about 25 mg / dose subcutaneously every 4 weeks for up to 6 doses) prior to transplantation. In one embodiment, a method for donor-specific antibody reduction and HL desensitization in a subject (e.g., a human subject) includes administering plasma exchange (or plasmapheresis) for 5, 6, or 7 times prior to transplantation, followed by administering an effective amount of IVIG (e.g., at up to about 2 g / kg of subject of 140 g) and administering an effective amount of clazakizumab (e.g., about 25 mg subcutaneously every 4 weeks for up to 6 doses). In a further embodiment, the method includes transplanting an allograft into the subject. In a further aspect, the allograft transplant is between the last administration of clazakizumab and about 270 days after administration of IVIG. This is shown in FIG. 5. In one embodiment, the effective amount of clazakizumab for reducing the level of DSA in an HLA-sensitized subject is about 12.5 mg / dose for 4, 5, 6 or more doses. In one embodiment, the effective amount of clazakizumab for reducing the level of DSA in an HLA-sensitized subject is about 25 mg / dose for 4, 5, 6 or more doses. In one embodiment, the effective amount of clazakizumab for reducing the level of DSA in an HLA-sensitized subject is not 25 mg / dose for 4, 5 or 6 monthly doses.

[0069] In another embodiment, a method for donor-specific antibody reduction and HL desensitization in a subject (e.g., a human subject) includes administering an effective amount of clazakizumab or an antigen-binding fragment thereof after transplantation (e.g., subcutaneously at about 25 mg every 4 weeks starting about 5-7 days after transplantation for up to 6 doses). In a further embodiment, the method includes administering an additional effective amount of clazakizumab (e.g., for up to 330 days after transplantation for an additional 6 doses). This is shown in FIG. 6. In one aspect, an effective amount of clazakizumab for reducing levels of DSA after solid organ transplantation in an HLA-sensitized subject is about 12.5 mg / dose for 1, 2, 3, 4, 5, or more doses. In one aspect, an effective amount of clazakizumab for reducing levels of DSA after solid organ transplantation in an HLA-sensitized subject is about 25 mg / dose for 1, 2, 3, 4, 5, or more doses. In one embodiment, an effective amount of clazakizumab for reducing levels of DSA following solid organ transplantation in HLA-sensitized subjects is not 25 mg / dose administered every 4 weeks.

[0070] In another embodiment, a method for donor-specific antibody reduction and HL desensitization in a subject (e.g., a human subject) includes administering an effective amount of clazakizumab or an antigen-binding fragment of clazakizumab prior to transplant (e.g., about 25 mg / dose subcutaneously every 4 weeks for up to 6 doses), and administering an effective amount of clazakizumab or an antigen-binding fragment thereof post-transplant (e.g., about 25 mg subcutaneously every 4 weeks starting about 5-7 days post-transplant for up to 6 doses).

[0071] Some embodiments of these methods provide for assaying biopsies from the patient and identifying stable levels of glomerular filtration rate (GFR) over time (e.g., less than 10%, 20%, or 30% variation over two, three, or four consecutive biopsies) and low levels of DSA (e.g., less than 10%, 20%, or 30%) compared to before the desensitization procedure or compared to previous biopsies performed after transplantation. In some embodiments, if the level of GFR is not stable or the level of DSA is high, the method further includes repeated administration of effective amounts of IVIG and clazakizumab until the level of GFR is stabilized and the level of DSA is low.

[0072] Yet another embodiment provides a method for donor-specific antibody reduction and HLA sensitization in a highly HLA sensitized subject (e.g., a human subject) by plasma exchange prior to transplantation. administering an effective amount of IVIG before, during, or after the transplant; and administering an effective amount of clazakizumab to the subject before, after, or both, wherein the subject has a stable level of glomerular filtration rate (GFR) over time (e.g., less than 10%, 20%, or 30% variation over two, three, or four consecutive biopsies) and a low level of DSA (e.g., less than 10%, 20%, or 30%) compared to before the desensitization procedure.

[0073] Following administration of clazakizumab as a 1-hour IV infusion, the pharmacokinetics of clazakizumab was linear over a dose range of 30 mg to 640 mg in healthy subjects and over a dose range of 80 mg to 320 mg in subjects with rheumatoid arthritis (RA), as demonstrated by consistent clearance at these dose levels. The T-half of clazakizumab at all doses was very similar in healthy male subjects and subjects with RA, consistent with that expected for a humanized IgG1 antibody. Across the doses tested, the mean T-half of clazakizumab ranged from 19.5 to 31.0 days in healthy male subjects and 26.4 to 30.9 days in subjects with RA. The T-half of clazakizumab following SC administration in healthy male subjects was similar to that of IV administration. In a phase 1 study comparing IV and SC administration in healthy male subjects, the mean T-half of clazakizumab was 30.7 days after a single IV dose and ranged from 31.1 to 33.6 days after SC administration. Bioavailability of clazakizumab after SC administration was 60% of that of the IV formulation. As expected, Cmax was lower and Tmax was longer with SC administration compared with IV administration.

[0074] Population PK analyses of clinical trial data in RA, PsA, and healthy subjects indicate that body weight affects the PK of clazakizumab such that both clearance and central volume of distribution increase with increasing body weight, and thus heavier subjects have less drug exposure compared to lighter subjects.

[0075] The effective dose of clazakizumab for a subject can be considered or limited based on the evaluation of safety.Safety evaluation includes interview, recording of adverse events, physical examination, blood pressure, and laboratory measurement.Subjects are generally evaluated at each study visit during their participation in this study for adverse events (all grades), serious adverse events, and adverse events that require interruption or discontinuation of study drug.

[0076] In some embodiments, a VLK antibody comprising clazakizumab, an IL-6 binding fragment of clazakizumab, or a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively, suitable for administration in the methods of the disclosure. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L An effective amount of a polypeptide having a polypeptide and a polypeptide combination may be administered over a total of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more doses, or as needed, about 10-50 μg / dose, 50-100 μg / dose, 100-150 μg / dose, 150-200 μg / dose, 100-200 μg / dose, 200-300 μg / dose, 300-400 μg / dose, 400-500 μg / dose, 500-600 μg / dose, 600-700 μg / dose, 700-800 μg / dose, 800-900 μg / dose, 900-1000 μg / dose, 1000-1500 μg / dose, 1500-200 μg / dose, 1000-2000 μg / dose, 2000-300 μg / dose, 3000-400 μg / dose, 4000-500 μg / dose, 5000-600 μg / dose, 6000-7000 μg / dose, 7000-8000 μg / dose, 8000-9000 μg / dose, 9000-10000 μg / dose, 10 ... 700μg / dose, 700~800μg / dose, 800~900μg / dose, 900~1000μg / dose, 1000~1100μg / dose, 1100~1200μg / dose, 1200~1300μg / dose, 1300~1400μg / dose, 1400~1500μg / dose Amount, 1500~1600μg / dose, 1600~1700μg / dose, 1700~1800μg / dose, 1800~1900μg / dose, 1900~2000μg / dose, 2000~2100μg / dose, 2100~2200μg / dose, 2200~2300μg / dose, 2 The dose may range from 300-2400 μg / dose, 2400-2500 μg / dose, 2500-2600 μg / dose, 2600-2700 μg / dose, 2700-2800 μg / dose, 2800-2900 μg / dose, or 2900-3000 μg / dose, and may be administered once daily, once weekly, once every two weeks, once a month, or once every two months, or a combination thereof.

[0077] In some embodiments, the amount of clazakizumab, an IL-6-binding fragment of clazakizumab, or a VD comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide comprised in SEQ ID NOs: 1, 2 or 3, and 4, respectively, suitable for administration in the disclosed method, per unit weight of the subject in the above method. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L Examples of effective amounts of a polypeptide having a polypeptide include 10 to 100 μg, 100 to 200 μg, 200 to 300 μg, 300 to 400 μg, 400 to 500 μg, 500 to 600 μg, 600 to 700 μg, 700 to 800 μg, 800 to 900 μg, 1 to 5 mg, 5 to 10 mg, 10 to 20 mg, 20 to 30 mg, 30 to 40 mg, 40 to 50 mg, 50 to 60 mg, 60 to 70 mg, 70 to 80 mg, 80 to 90 mg, 90 to 100 mg, 100 to 200 mg, 200 to 300 mg, 300 to 400 mg, 400 mg to 500 mg, 500 mg to 1 g, or 1 g to 10 g. The unit weight of the subject can be per kg of body weight or per subject.In one embodiment, the effective amount of clazakizumab for reducing and desensitizing the level of DSA in a human subject who is already HLA-sensitized and needs or has received a renal allograft is about 25mg / month.In one embodiment, the effective amount of clazakizumab for reducing and desensitizing the level of DSA in a human subject who is already HLA-sensitized and needs or has received a renal allograft is not about 25mg / month.

[0078] In further embodiments, a VLK antibody comprising clazakizumab, an IL-6-binding fragment of clazakizumab, or a CD1R polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide comprised in SEQ ID NOs: 1, 2 or 3, and 4, respectively, suitable for administration in the methods of the disclosure. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. LAn effective amount of a polypeptide having a polypeptide can be in the range of 0.01-0.05 mg / kg, 0.05-0.1 mg / kg, 0.1-1 mg / kg, 1-5 mg / kg, 5-10 mg / kg, 10-50 mg / kg, 50-100 mg / kg. In additional embodiments, an effective amount of clazakizumab, an antigen-binding fragment of clazakizumab, or a polypeptide of the disclosure is about 1-2 mg / kg, 2-3 mg / kg, 3-4 mg / kg, 4-5 mg / kg, 5-6 mg / kg, 6-7 mg / kg, 7-8 mg / kg, 8-9 mg / kg, 9-10 mg / kg, 10-11 mg / kg, 11-12 mg / kg, 12-13 mg / kg, 13-15 mg, 15-20 mg / kg, or 20-25 mg / kg. In additional embodiments, an effective amount of clazakizumab, an antigen-binding fragment of clazakizumab, or a polypeptide of the disclosure is any one or more of about 100-125 mg, 125-150 mg, 150-175 mg, 160-170 mg, 175-200 mg, 155-165 mg, 160-165 mg, 165-170 mg, 155-170 mg, or a combination thereof, which may be administered over 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 doses, some of which are pre-transplant and others post-transplant.

[0079] In various embodiments, a VLK antibody comprising clazakizumab, an IL-6 binding fragment of clazakizumab, or a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively, suitable for administration in the methods of the disclosure. H a polypeptide and a CDR1 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively; V comprising a CDR2 polypeptide and a CDR3 polypeptide LThe polypeptide having the polypeptide and the polypeptide are administered at least once, 1-7 times per week, 1-7 times per month, or 1-12 times per year, or one or more times as needed, for 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 14 months, 16 months, 18 months, about 24 months, about 30 months, about 36 months, or a combination thereof, at least once, 1-7 times per week, 1-7 times per month, or 1-12 times per year, or one or more times as needed, at any one or more of the dosages described herein.

[0080] Pharmaceutical Compositions In various embodiments, the present invention provides pharmaceutical compositions, comprising: (1) clazakizumab, an IL-6-binding fragment of clazakizumab, or a V-seq antibody comprising the CDR1, CDR2, and CDR3 polypeptides contained in SEQ ID NOs: 1, 2, or 3, and 4, respectively; H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L and (2) a pharma- ceutically acceptable excipient.

[0081] The pharmaceutical composition of the present invention may include any pharma- ceutically acceptable excipient. By "pharma-ceutically acceptable excipient" is meant an excipient that is generally safe, non-toxic, and useful in the preparation of a desired pharmaceutical composition, including excipients that are acceptable for human pharmaceutical use as well as for veterinary use. Such excipients may be solid, liquid, semi-solid, or, in the case of aerosol compositions, gaseous. Examples of excipients include, but are not limited to, amino acids, starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrants, wetting agents, emulsifiers, colorants, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives, antioxidants, plasticizers, gelling agents, thickeners, hardeners, setting agents, suspending agents, surfactants, humectants, carriers, stabilizers, and combinations thereof.

[0082] In one embodiment, the method of the disclosure includes a method for administering to a patient a polypeptide comprising L-histidine, L-histidine monohydrochloride, sorbitol, polysorbate-80, and water for injection, and clazakizumab, an IL-6 binding fragment of clazakizumab, or a V polypeptide comprising the CDR1 polypeptide, the CDR2 polypeptide, and the CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L The method includes administering a pharmaceutical composition comprising the polypeptide and a polypeptide having the polypeptide.

[0083] In various embodiments, the pharmaceutical composition of the present invention may be formulated for delivery by any route of administration. In one embodiment, the pharmaceutical composition is administered intravenously or subcutaneously to a subject. "Route of administration" may refer to any route of administration known in the art (e.g., but not limited to, aerosol, nasal, oral, mucosal, transdermal, parenteral, or enteral). "Parenteral" refers to a route of administration that generally involves injection (e.g., intraorbital, infusion, intraarterial, intraarticular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal). By parenteral route, the composition may be in the form of a solution or suspension for injection or as a lyophilized powder. By parenteral route, the composition may be in the form of a solution or suspension for injection or for injection. By enteral route, the pharmaceutical composition can be in the form of tablets, gel capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres, or lipid or polymer vesicles capable of controlled release. Typically, the composition is administered by injection. These methods of administration are known to those skilled in the art.

[0084] The pharmaceutical composition of the present invention may include any pharma- ceutically acceptable carrier. As used herein, "pharma-ceutically acceptable carrier" refers to a pharma-ceutically acceptable substance, composition, or vehicle involved in carrying or transporting a compound of interest from one tissue, organ, or part of the body to another tissue, organ, or part of the body. For example, the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof. Each component of the carrier must be "pharma-ceutically acceptable" in that it must be compatible with the other components of the formulation. Similarly, it must be suitable for use in contact with any tissue or organ that it may come into contact with, meaning that it must not pose a risk of toxicity, irritation, allergic reaction, immunogenicity, or any other complication that excessively outweighs the therapeutic benefit.

[0085] The pharmaceutical compositions of the present invention may also be encapsulated, tableted, or prepared in emulsion. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, facilitate preparation of the composition, or provide sustained or controlled release (or increased half-life) of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohol, and water. Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar, or gelatin. Emulsion carriers include liposomes or controlled release polymeric nanoparticles known in the art. Methods for preparing liposome delivery systems are discussed in Gabizon et al., Cancer Research (1982) 42:4734; Cafiso, Biochem Biophys Acta (1981) 649:129; and Szoka, Ann Rev Biophys Eng (1980) 9:467. Other drug delivery systems are known in the art and are described, for example, in Poznansky et al., DRUG DELIVERY SYSTEMS (RL Juliano, ed., Oxford, NY 1980), pp. 253-315; ML Poznansky, Pharm Revs (1984) 36:277. Carriers can also include sustained release materials such as glyceryl monostearate or glyceryl distearate, alone or together with wax.

[0086] The pharmaceutical preparations are manufactured according to conventional techniques of pharmacy (e.g., milling, mixing, granulating, and, if necessary, compressing, for tablet forms; or milling, mixing, and filling, for hard gelatin capsule forms). When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, or an aqueous or non-aqueous suspension. Such liquid preparations may be administered directly po or filled into soft gelatin capsules.

[0087] The pharmaceutical composition of the present invention may be delivered in a therapeutically effective amount. The precise therapeutically effective amount is the amount of the composition that will give the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending on a variety of factors, including but not limited to the characteristics of the therapeutic compound (e.g., activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological state of the subject (e.g., age, sex, type and stage of disease, general physical condition, responsiveness to a given dosage, and type of drug), the nature of the pharmacologic carrier in the formulation, and the route of administration. Those skilled in the clinical and pharmacological arts can determine therapeutically effective amounts by routine experimentation, for example, by monitoring the subject's response to administration of the compound and adjusting the dosage accordingly. For further guidance, see Remington: The Science and Practice of Pharmacy (Gennaro ed. 20th edition, See Williams & Wilkins PA, USA (2000).

[0088] Prior to administration to a patient, the formulant may be mixed with clazakizumab, an IL-6-binding fragment of clazakizumab, or a VDG comprising the CDR1 polypeptide, the CDR2 polypeptide, and the CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L A liquid formulation may be preferred. For example, the formulating agent may include oils, polymers, vitamins, carbohydrates, amino acids, salts, buffers, albumin, surfactants, bulking agents, or combinations thereof.

[0089] Carbohydrate formulating agents include sugars or sugar alcohols (e.g., monosaccharides, disaccharides, or polysaccharides), or water-soluble glucans. Saccharides or glucans may include fructose, dextrose, lactose, glucose, mannose, sorbose, xylose, maltose, sucrose, dextran, pullulan, dextrin, alpha-cyclodextrin and beta-cyclodextrin, soluble starch, hydroxyethyl starch, and carboxymethylcellulose, or mixtures thereof. "Sugar alcohol" is defined as a C4-C8 hydrocarbon having an -OH group, and includes galactitol, inositol, mannitol, xylitol, sorbitol, glycerol, and arabitol. These sugars or sugar alcohols mentioned above may be used alone or in combination. There is no limit to the amount used, so long as the sugar or sugar alcohol is soluble in the aqueous preparation. In one embodiment, the concentration of the sugar or sugar alcohol is 1.0 w / v % to 7.0 w / v %, more preferably 2.0 to 6.0 w / v %.

[0090] Amino acid formulating agents include the levorotatory (L) forms of carnitine, arginine, and betaine, although other amino acids may be added.

[0091] In some embodiments, polymers as formulants include polyvinylpyrrolidone (PVP) having an average molecular weight of 2,000 to 3,000 or polyethylene glycol (PEG) having an average molecular weight of 3,000 to 5,000.

[0092] It is also preferred to use a buffer in the composition to minimize pH changes in the solution before lyophilization or after reconstitution. Most physiological buffers (such as, but not limited to, citrate, phosphate, succinate, and glutamate buffers, or mixtures thereof) may be used. In some embodiments, the concentration is 0.01 to 0.3 molar. Surfactants that may be added to the formulation are shown in European Patents 270,799 and 268,110.

[0093] After preparing the liquid pharmaceutical composition, the liquid pharmaceutical composition can be lyophilized to prevent degradation and maintain sterility. Methods for lyophilizing liquid compositions are known to those skilled in the art. Just before use, the composition can be reconstituted with a sterile diluent (e.g., Ringer's solution, distilled water, or sterile saline) that may contain additional ingredients. Once reconstituted, the composition is administered to a subject using methods known to those skilled in the art.

[0094] Anti-infective agents Various embodiments provide that the method of desensitization further comprises administering one or more anti-infective agents as prophylaxis or treatment against bacterial, viral, or fungal infection, preferably after transplantation.

[0095] Exemplary anti-infective agents suitable for use in the methods of the present disclosure include: antibiotics, such as aminoglycosides (e.g., amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin), ansamycins (e.g., geldanamycin, herbimycin), carbacephems (e.g., loracarbef), carbapenems (e.g., ertapenem, doripenem, imipenem, cilastatin, meropenem), serotonin, and the like. Phalosporins (e.g., 1st generation: cefadroxil, cefazolin, cefalotin or cefalothin, cephalexin; 2nd generation: cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime; 3rd generation: cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone; 4th generation: cefepime;5th generation: ceftobiprole), glycopeptides (e.g., teicoplanin, vancomycin), macrolides (e.g., azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spectinomycin), monobactams (e.g., aztreonam), penicillins (e.g., amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin, nicillin, piperacillin, ticarcillin), polypeptide antibiotics (e.g., bacitracin, colistin, polymyxin b), quinolones (e.g., ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, trovafloxacin), rifamycins (e.g., rifampicin or rifampin, rifabutin, rifapentine, rifaximin), sulfonamides (e.g., mafenide, prontosil, sulfacetamide, sulfamethizole, cyclosporine, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (cotrimoxazole, "tmp-smx"), and tetracyclines (e.g., demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline), as well as arsphenamine, chloramphenicol, clindamycin, lincomycin, ethambutol, fosfomycin, fusidic acid, furazolidone, isoniazid, linezolid, metronidazole, mupirocin, Nitrofurantoin, platensimycin, pyrazinamide, quinupristin / dalfopristin combination, and tinidazole. In some embodiments, a method of reducing donor-specific antibodies in an HLA-sensitized subject prior to and / or after allograft transplantation comprises administering to the subject an effective amount of clazakizumab, or an IL-6-binding antibody fragment of clazakizumab, and administering to the subject an effective amount of ganciclovir, valganciclovir, fluconazole, trimethoprim, sulfamethoxazole, or a combination thereof;

[0096] kit In various embodiments, the present invention provides a kit for desensitization of an organ transplant recipient, comprising a collection of materials or components (e.g., clazakizumab, an IL-6 binding fragment of clazakizumab; or a VD comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively). H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L a polypeptide having a polypeptide; instructions or manual for administration for desensitization before and after organ transplantation; one or more vessels as a container; and, optionally, one or more diluents.

[0097] The exact nature of the components comprised in the kit of the invention will depend on its intended purpose. In one embodiment, the kit is specifically adapted for human subjects. In one embodiment, the kit is configured for veterinary use to treat subjects such as, but not limited to, livestock, farm animals, and laboratory animals.

[0098] The kit may include instructions for use. "Instructions for use" typically include tangible expressions that explain the techniques used in using the components of the kit to produce a desired outcome (e.g., to treat or inhibit cancer cachexia in a subject). Optionally, the kit also includes other useful components, such as measuring instruments, diluents, buffers, pharma- ceutically acceptable carriers, syringes, or other useful tools that will be readily recognized by those skilled in the art.

[0099] The materials or components that assemble the kit may be stored and provided to the practitioner in any convenient and suitable manner that maintains their operability and utility. For example, the components may be in dissolved, dehydrated, or lyophilized form and may be provided at room, refrigerated, or frozen temperatures. The components are typically housed in suitable packaging materials. As used herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as the compositions of the present invention and the like. The packaging material is constructed by well-known methods and is preferably configured to provide a sterile, uncontaminated environment. As used herein, the term "packaging" refers to a suitable solid matrix or material (e.g., glass, plastic, paper, foil, and the like) that can hold the individual kit components. Thus, for example, the packaging may be a suitable solid matrix or material that can hold the individual kit components, such as clazakizumab, an IL-6 binding fragment of clazakizumab, or a VD containing the CDR1 polypeptide, CDR2 polypeptide, and CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L The packaging material may be a bottle used to contain an appropriate amount of a composition of the invention comprising a polypeptide having a polypeptide and a polypeptide chain. The packaging material generally has an exterior label indicating the contents and / or purpose of the kit and / or its components. EXAMPLES

[0100] The following examples are provided to better illustrate the claimed invention and should not be construed as limiting the scope of the invention. To the extent that specific materials are mentioned, the materials are merely for illustrative purposes and are not intended to limit the invention. Those skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

[0101] STUDY:A phase I / II study to evaluate the safety and tolerability of clazakizumab to remove donor-specific HLA antibodies and improve transplant rates in highly HLA-sensitized (HS) patients awaiting kidney transplantation. This study is an open-label design to evaluate the safety and efficacy of clazakizumab in removing DSA and inducing Treg subsets in HS patients awaiting HLA-mismatched (HLAi) kidney transplants. The protocol is outlined in Figures 5 and 6. The safety determination aims to evaluate any side effects associated with administration of clazakizumab and the risk of infectious complications associated with clazakizumab treatment for desensitization of HS patients awaiting kidney HLAi transplants. The limited efficacy determination includes evaluation of the reduction of DSA levels allowing for an increase in engraftment rates and the subsequent prevention of ABMR (eGFR, SCr) after clazakizumab treatment.

[0102] The investigational drug, clazakizumab, has an active ingredient, a genetically engineered humanized anti-IL-6 monoclonal antibody. As manufactured by Ajinomoto Althea (San Diego CA), clazakizumab has a strength of 25 mg / mL. Clazakizumab is formulated with L-histidine, L-histidine monohydrochloride, sorbitol, polysorbate-100, sorbitol-100 phosphate-binding phosphate (PBS), and sorbitol-100 phosphate-binding phosphate (PBS). It contains excipients including 0.80 mg / mL, 0.80 mg / mL, and water for injection. It is supplied in a single-dose vial of 25 mg / mL for undiluted injection. Clazakizumab vials should be stored at or below -20°C (-4°F) protected from light. Prepared syringes may be stored in a refrigerator at 2-8°C (36-46°F) ≤ -20°C (-4°F) for up to 24 hours, with up to 4 hours of that 24-hour period stored at room temperature between 15-25°C (59-77°F). Prepared syringes should be protected from light. Prior to administration, clzakizumab should be brought to room temperature by storing without refrigeration for 30-60 minutes before use.

[0103] procedure This was a phase I / II clinical trial of clazakizumab in highly HLA-sensitized patients awaiting kidney transplantation. The study was intended to last 3 years. HLA antibodies were detected using a solid-phase assay system currently used at the Cedars-Sinai Medical Center HLA Laboratory.

[0104] Typically, patients participating in this study received PLEX (5-7 doses) + IVIG initially, followed by clazakizumab 25 mg subcutaneously (SC) 1 week after IVIG. If no safety / tolerability / efficacy issues were observed after the first dose, the patient received 5 additional injections every 4 weeks (Q4W). If the patient received an HLAi transplant, clazakizumab was continued at 25 mg SC Q4W for 6 doses (starting 5 days after transplant) for 6M post-transplant. Protocol biopsies were performed 6M post-transplant to evaluate the allograft for evidence of ABMR, including C4d staining and TG, using the Banff 2015 criteria. If improvement was seen after the 6th dose of clazakizumab, the patient would continue for another 6 doses for 6 months. Patients who developed evidence of persistent allograft dysfunction may undergo non-protocol biopsies for this cause. Patients who received 12 doses of clazakizumab after transplant would undergo a 12M protocol biopsy. If a patient did not show improvement after receiving 6 doses of clazakizumab, they would receive no further treatment and would return on day 365 for the final study visit.

[0105] Specifically, one dose of IVIG was administered at the time of transplant (day 0) (IVIG #1). A second dose of IVIG was administered on day 1. The treatment period then began. Clazakizumab was administered six times on days 5 ± 2d, 30 ± 7d, 60 ± 7d, 90 ± 14d, 120 ± 14d, and 150 ± 14d, respectively.

[0106] Figure 7 shows the study timeline for patient ClazaDes03 and his creatinine levels over time. Patient "ClazaDES03" is a 32 year old male with a history of end stage renal failure secondary to unclear etiology. This patient is post-living related kidney transplant in 2012 which failed in 2016. For patient "ClazaDES03", the transplant was performed after the first dose of clazakizumab (25 mg subcutaneous) and before the second dose of clazakizumab. This patient received PLEX (5-7 doses) on day -15; IVIG at 2g / kg on day 0; post-transplant #1 clazakizumab (25mg SQ) on day 7 (April 5, 2018); deceased donor kidney transplant on day 21 (April 29, 2018); post-transplant #1-#6 clazakizumab (25mg SQ) at approximately monthly intervals; induction with alemtuzumab (CAMPATH 1H) and maintenance with tacrolimus, mycophenolate mofetil (MMF), and prednisone. Approximately 2 months after transplant, on June 28, 2018, a renal allograft biopsy was examined (Figure 8) showing suboptimal creatinine levels, and on August 14, 2018, monthly administration of belatacept was initiated. On October 23, 2018, a 6M biopsy was examined (Figure 9). Starting on October 31, 2018, the second round (#7 to #12) of clazakizumab was administered (#7 post-transplant clazakizumab). For this patient, no donor-specific antibodies were present after transplant.

[0107] Anti-HLA antibodies may occur naturally or may arise from previous pregnancies, blood transfusions, or previous transplants. Patients treated with six doses of clazakizumab for desensitization underwent blood sampling for HLA antibodies, other monitoring of blood samples, and immunological testing. If the patient received an HLAi transplant during this study, they received clazakizumab 25 mg subcutaneously every 4 weeks for six doses, with standard post-transplant immunosuppression protocols and immune monitoring. Immune monitoring of blood samples was performed at Cedars-Sinai Transplant Immunology Laboratory, including Treg, Tfh, Th17, and B cell subsets, as well as IL-6 and CRP monitoring.

[0108] result Figure 1 shows the DSA profile in this study for subject "ClazaDES01," a 50 year old African American female with a history of end stage renal disease (ESRD) secondary to biopsy proven focal segmental glomerulosclerosis (FSGS), on dialysis since November 2008 (i.e., approximately 10 year waiting period for B+ blood type), with a calculated panel reactive antibody (cPRA) of 58%. The patient's sensitizing events included 4 pregnancies and blood transfusions.

[0109] Figure 2 shows the DSA profile for subject "ClazaDES05" before and after transplantation. (Median Fluorescence Intensity, MFI). Subject "ClazaDES05" is a 36-year-old female with a history of ESRD secondary to IgA nephropathy, has been on dialysis since June 2008 (i.e., approximately 10 years waiting period for A+ blood type), and has a cPRA of 100%. The patient's sensitization events included previous transplants and blood transfusions. Subject "ClazaDES05" received a kidney transplant from a deceased donor after four doses of clazakizumab. The patient had two types of DSA (Class I and II). DSA intensity decreased from MFI>12,500 MFI at transplantation to MFI=0 10 days after transplantation for Class I, and from MFI>17,500 at transplantation to MFI>3250 10 days after transplantation for Class II. Per study protocol, patients continued monthly clazakizumab for 6 months after transplantation.

[0110] FIG. 3A shows the overall C-reactive protein levels in the clazakizumab desensitization study. Overall, C-reactive protein (CRP) decreased from baseline to nearly zero at 2 months. The number of subjects included in the analysis at each time point is shown in brackets. FIG. 3B shows the individual C-reactive protein levels in the clazakizumab desensitization study from baseline to month 7.

[0111] Figure 4 shows the sum of MFI over time from pre-plasma exchange (PLEX) (pre-PLEX) to the 5th dose of clazadesumab (N=9). Typically, MFI tends to recover approximately 1-3 months after completion of PLEX / IVIG. Here, with monthly clazadesumab injections, the sum of MFI continued to decrease over time when compared to pre-PLEX. To date, three patients have undergone transplantation. Patients ClazaDES01 and ClazaDES03 underwent transplantation after the 1st dose of clazadesumab. Patient ClazaDES05 underwent transplantation after the 4th dose of clazadesumab.

[0112] For patient "ClazaDES03," Figure 7 shows this patient's creatinine (mg / dL) levels over time, comparing pre-desensitization treatment to post-desensitization treatment and kidney transplant. Creatinine was maintained at low levels post-transplant with two doses of clazakizumab post-transplant. Figure 8 shows a 2-month kidney transplant biopsy from patient "ClazaDES03." This biopsy showed mild acute tubular injury; mild to moderate arteriosclerosis; and mild atherosclerosis. The biopsy showed no signs of disease (which was consistent with donor disease); no diagnostic evidence of acute rejection (almost bordering on cell-mediated rejection by Banff criteria); mesangial IgA deposits were present, but there were no associated proliferative glomerular changes. The absence of IgA staining in a biopsy from the patient's previous kidney transplant in 2012 suggested that the IgA present in this biopsy was likely donor-related. Figure 9 shows a 6-month kidney transplant biopsy from patient "ClazaDES03." In this biopsy, there was acute tubular necrosis with rare, uniform-sized vacuoles; mild tubulointerstitial inflammation (almost bordering on cell-mediated rejection); arteriosclerosis; and minimal interstitial fibrosis / tubular atrophy. Rare, uniform-sized vacuoles were detected, which may be related to acute calcineurin inhibitor toxicity of recent IVIG treatment. Diagnostic features of antibody-mediated rejection or polyomavirus nephropathy were not present.

[0113] Overall, desensitization treatment with clazakizumab reduced HLA antibodies and allowed engraftment in at least 40% of patients in this study.

[0114] A total of 10 patients were enrolled between March and November 2018. Nine patients were enrolled; eight were engrafted during the study period and the ninth patient was engrafted 2 months after completion of the study. Four patients reached the 12-month study period. All infusions administered were well tolerated. No graft losses or patient deaths were observed, and no significant infections attributable to clazakizumab or requiring discontinuation of clazakizumab were observed. Renal function at 6 months was stable. Demographic and immunological / transplant characteristics are summarized in Tables 1 and 2.

[0115] [Table 1]

[0116] [Table 2]

[0117] All but the ninth patient underwent 6-month protocol biopsies. Two patients (25) had biopsy-proven rejection: one patient with chronic active cell-mediated rejection, Banff grade 1A; one patient with chronic active antibody-mediated and cell-mediated rejection, Banff grade 1B. Both patients responded to treatment according to the study center's standard of care protocol.

[0118] Seven of nine patients (78%) who underwent transplant had DSA before desensitization and at the time of transplant. Only three patients (33%) had DSA detected at 1 month; two patients (22%) had DSA detected at 3 months; no patients had DSA detected at 6 months (6M), 9 months (9M), or 12 months (12M) (including patients with DSA detected at 1 month and 3 months). Before desensitization, DSA MFI values ​​(mean ± SD) at transplant, 1 month, and 3 months were as follows: 11060 ± 6990, 7980 ± 6260, 1923 ± 3973, 1040 ± 2650; and 0 ± 0 at 6M, 9M, and 12M, respectively. Mean DSA MFI was significantly decreased when comparing pre-desensitization to 1M (p=0.0004) and 3M (p=0.0001) and when comparing implantation to 1M (p=0.007) and 3M (p=0.001).

[0119] Seven SAEs occurred, none of which appeared related to clazakizumab, including wound dehiscence requiring wound reclosure (1 SAE), hematuria and UTI before receiving the first dose of study drug (1 SAE) and bacteremia (1 SAE), thrombosis of the right external iliac artery with graft loss (1 SAE), persistent surgical site pain requiring CT-guided drainage of peri-transplant fluid with MSSA growth (1 SAE), chronic biopsy-proven active ABMR as a result of delayed clazakizumab administration d / t infection and chronic thrombocytopenia (1 SAE), and perinephric effusion requiring CT-guided drainage (1 SAE).

[0120] Major secondary objectives To determine whether clazakizumab treatment could significantly reduce or eliminate ABMR development and C4d deposition in mismatched allografts transplanted into highly HLA-sensitized patients after clazakizumab desensitization. Allograft function was assessed up to 6-12 months (6-12M) after transplantation, and renal function was determined using serum creatinine (SCr), Modification of Diet in Renal Disease (MDRD) GFR calculations (for patients under 18 years of age, the Schwartz equation was used to estimate creatinine clearance (CrCl)), and DSA levels. Protocol biopsies were performed 6M after clazakizumab treatment. In addition, several immunological measures of blood samples were evaluated at time points before and after the initiation of clazakizumab treatment. These included: T reg Cells (CD4+, CD25+, FoxP3+CD127 dim ) Evaluation T fh Evaluation of cells (CD4+, ICOS+, CXCR5+, IL-21+) Assessment of circulating plasmablasts (CD19+, CD38+, CD27+, IL-6+) Assessment of CRP and IL-6 levels.

[0121] These secondary endpoints will help understand the biology of the alloimmune response to the allograft and to determine the potential and mechanism of beneficial effects of clazakizumab. Viral PCR was monitored according to standard of care.

[0122] Inclusion criteria Age 15-75 years at screening. HS patients awaiting DD or LD kidney transplant on the UNOS list (cPRA ≥ 50%). History of pregnancy, blood transfusion, and / or kidney transplant. Subject / parent / guardian must be willing to participate fully through the study requirements. Subject / parent / guardian must understand and be able to provide informed consent. Pneumococcal vaccination. Negative tuberculin (ppd) placement result or negative Quantiferon TB Gold result. These individuals must also have sufficient waiting time on the UNOS list to allow frequent overtures with a history of positive crossmatch (DD) or mismatch (LD) by positive flow cytometry (FCMX) and negative complement dependent cytotoxicity (CDC+) crossmatch. Patients proceeding to HLAi transplant after desensitization will have CDC CMX negativity at 1:2 dilution, channel shift of FCMX < 225, and DSA with acceptable MFI as previously defined.

[0123] Exclusion criteria Multiple organ transplants (e.g., kidney and pancreas). Intolerance to treatment with clazakizumab or other IL-6 inhibitors. Breastfeeding or pregnant women. Women of childbearing age and male partners of women of childbearing age who are unwilling or unable to use an FDA-approved form of contraception during the study and for 5 months after the last dose. HIV positive subjects. Subjects who tested positive for HBV or HCV infection by HBVeAg / DNA [positive anti-HCV (EIA) and confirmed HCV RIBA]. Subjects with latent or active TB. Subjects must have a negative Quantiferon TB Gold test result. Recent recipient of any licensed or investigational live attenuated vaccine within 2 months of screening visit (e.g., including but not limited to, any of the following: adenovirus [Adenovirus Vaccine Live Oral Type 7], Chickenpox [Varivax], Hepatitis A [VAQTA], Rotavirus [Rotashield], Yellow Fever [YF-Vax], Measles and Mumps [Measles and Mumps Virus Vaccine Live], Measles, Mumps, and Rubella Vaccine [MMR-II], Sabin Oral Polio Vaccine, and Rabies Vaccine [IMOVAX Rabies ID, RabAvert]). ANC<2000, platelet count<100×10 3 / ml, and grossly abnormal general serum screening test results defined as SGOT or SGPT >1.5 × upper limit of normal. Individuals deemed unable to follow the protocol. Subjects with active CMV or EBV infection defined by CMV-specific serology (IgG or IgM) and confirmed by quantitative PCR, with or without compatible disease (quantitative PCR cutoff defined as having >50 copies of CMV or EBV DNA / PCR). Use of study medication within 4 weeks of participation. History or activity of inflammatory bowel disease, or diverticular disease, or gastrointestinal perforation. Recent infection (within the past 6 weeks prior to screening) requiring the use of any antibody (oral, parenteral, or topical). Current or past (within 5 years) malignancies except basal cell carcinoma, completely excised squamous cell carcinoma of the skin, or cervical intraepithelial neoplasia that has not recurred (within 5 years).

[0124] Applicant also conducted a study evaluating the cost / benefit analysis of desensitization compared to dialysis. The costs associated with transplantation after desensitization, including the costs of all medications, organ procurement, treatment of rejection episodes, and return to dialysis for those who lost their allografts, compared favorably to the costs of continuing dialysis over the same period. Most importantly, in this cohort, there was a survival benefit to transplantation. At 3 years, the mortality rate for desensitized transplanted patients was 3.5% compared to 22.8% for those who remained on dialysis.

[0125] If rejection (biopsy-proven) developed during the study, patients were treated with "pulse" methylprednisolone (10 mg / kg / day, up to 1000 mg if >100 kg, for 3 days) and antithymocyte globulin (1.5 mg / kg once daily x 4) for development of cell-mediated rejection unresponsive to pulse steroids. Patients who relapsed with antibody-mediated rejection (ABMR) after treatment with study drugs were initially administered pulse methylprednisolone (10 mg / kg / day, up to 1000 mg if >100 kg) IV once daily x 3 doses, then, depending on severity, IVIG 10% solution 2 mg / kg (up to 140 g if >70 kg) IV x 1 dose, followed by rituximab (375 mg / m 2 ) IV x 1 dose was administered. If there was a rapid decline in allograft function and / or thrombotic microangiopathy was diagnosed, patients underwent plasma exchange for 3-5 sessions followed by anti-C5 (Eculizumab®) IV once a week for 4 weeks (1200 mg week 1, followed by 900 mg / week for an additional 3 weeks). Efficacy of treatment was assessed by determining improvement in renal function and monitoring DSA response, with repeat allograft biopsy as necessary. For the purposes of this study, ABMR was defined as: decline in allograft function (defined as a decline of >30% from baseline) in high-risk transplant recipients (i.e., sensitized patients with a history of DSA) as measured by serum Cr and eGFR; association with the presence of vascular endothelial cell carcinoma (usually increased in intensity); and biopsy evidence based on the BANFF 2015 grading (e.g., capillaritis, inflammation, and C4d deposition).

[0126] Adverse events (AEs) and serious adverse events were monitored after treatment with clazakizumab. These included close attention to infectious complications that may be related to clazakizumab treatment. Our group evaluated infectious complications associated with desensitization with IVIG + rituximab and alemtuzumab induction treatment and subsequent maintenance treatment with tacrolimus, MMF, and prednisone. With the use of this desensitization protocol and subsequent alemtuzumab induction, the risk of common or serious infections after transplant is not increased compared to patients in the low-risk group. Serious infections were defined as any viral infection, and any fungal or bacterial infection requiring iv antibiotics or hospitalization. Therefore, the risk of infection in the study group (clazakizumab) after ABMR treatment is likely to be similar and comparable to non-sensitized patients. All patients enrolled in this study required vaccination with Streptococcus pneumoniae.

[0127] In this study, all study patients received IV ganciclovir during hospitalization and IV valganciclovir during outpatient care, with doses adjusted for renal function, for 6 months after kidney transplantation, regardless of their cytomegalovirus (CMV) status. Fungal prophylaxis was achieved with fluconazole 100 mg once daily for 1 month after transplantation. Pneumocystis jirovecii pneumonia and bacterial prophylaxis was achieved with trimethoprim 80 mg and sulfamethoxazole 400 mg once daily for 12 months after transplantation. Viral polymerase chain reaction assays for CMV, Epstein-Barr virus, parvovirus B-19, and polyomavirus BK and JC were performed on study patients monthly for 6 months after transplantation.

[0128] Various embodiments of the present invention have been described above in detailed description. These descriptions directly describe the above embodiments, but it is understood that those skilled in the art may think of modifications and / or variations to the specific embodiments shown and described herein. Any such modifications or variations that are within the scope of this description are intended to be included in the present specification as well. Unless specifically stated otherwise, it is the intention of the inventors that the words and phrases in this specification and claims are given their ordinary and customary meaning to those skilled in the relevant field.

[0129] The above description of various embodiments of the present invention known to the applicant at the time of filing this application has been presented for purposes of illustration and description, and is intended to be so. This specification is not intended to be exhaustive or to limit the invention to the precise form disclosed, and many modifications and variations are possible in light of the above teachings. The described embodiments serve to illustrate the principles of the present invention and its practical application, enabling those skilled in the art to utilize the invention in various embodiments and with various modifications suitable for the particular use envisaged. Therefore, it is not intended that the invention be limited to the specific embodiments disclosed for carrying out the invention.

[0130] While particular embodiments of the present invention have been shown and described, it will be apparent to those skilled in the art that, based on the teachings herein, changes and modifications may be made without departing from the present invention and its broader aspects, and therefore, the appended claims are intended to encompass within their scope all changes and modifications that are within the true spirit and scope of the present invention. In general, it will be understood by those skilled in the art that the terms used herein are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including but not limited to," the term "having" should be interpreted as "having at least," the term "include" should be interpreted as "including but not limited to," etc. (It is.)

[0131] As used herein, the terms "comprising" or "comprise" are used in reference to compositions, methods, and each component thereof that are useful in an embodiment, and are also open to the inclusion of unspecified elements, whether or not useful. In general, those of skill in the art will understand that the terms used herein are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including, but not limited to," the term "having" should be interpreted as "having at least," and the term "include" should be interpreted as "including, but not limited to"). Although the open-ended term "comprising" is used herein to describe and claim the invention, as a synonym for terms such as including, containing, or having, the invention or embodiments thereof may be described using alternative terms such as "consisting of" or "consisting essentially of."

[0132] Unless otherwise indicated, all numbers expressing quantities should be understood in all cases to be modified by the term "about". The term "about" may refer to ±10% of the value referred to. When specifically defined and claimed, the term "about" may refer to ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% of the value referred to; for example, a claim may state that a value is about X, and that about is ±6%.

[0133] When a range of values ​​is described, each numerical value between and including the upper and lower limits of the range is intended to be disclosed herein. It should be understood that any numerical range recited herein is intended to include all subranges contained within the range. For example, a range of "1 to 10" is intended to include all subranges between and including the recited minimum value of 1 and the recited maximum value of 10; i.e., a minimum value of 1 or more and a maximum value of 10 or less. The numerical ranges of the present disclosure are continuous, and therefore include every value between the minimum and maximum values.

Claims

1. 1. A method for reducing and / or eliminating donor-specific antibodies in a human leukocyte antigen (HLA)-sensitized subject, comprising: Clazakizumab; an interleukin-6 (IL-6) binding fragment of Clazakizumab; or a V comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L administering to the subject an effective amount of a polypeptide having the polypeptide. Including, the subject is in need of or has undergone a solid organ transplant; The method.

2. administering to a subject an effective amount of a pharmaceutical composition comprising: Clazakizumab; an IL-6 binding fragment of Clazakizumab; or a V comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 1, 2 or 3, and 4, respectively. H and a V polypeptide comprising a CDR1 polypeptide, a CDR2 polypeptide, and a CDR3 polypeptide contained in SEQ ID NOs: 5, 6, and 7, respectively. L a polypeptide having a one or more pharma- ceutically acceptable excipients; 2. The method of claim 1, wherein said administering comprises:

3. 3. The method of claim 1 or 2, wherein the clazakizumab, an IL-6 binding fragment of clazakizumab, or the polypeptide is administered prior to solid organ transplantation.

4. 3. The method of claim 1 or 2, wherein the clazakizumab, IL-6 binding fragment of clazakizumab, or polypeptide is administered after solid organ transplantation, during solid organ transplantation, or both.

5. 3. The method of claim 1 or 2, wherein the clazakizumab, IL-6 binding fragment of clazakizumab, or polypeptide is administered both before and after solid organ transplantation.

6. 3. The method of claim 1 or 2, further comprising administering standard of care treatment comprising intravenous immunoglobulin (IVIG) administration, rituximab administration, plasma exchange, or a combination thereof.

7. 7. The method of claim 6, wherein the standard of care treatment is administered prior to clazakizumab, an IL-6 binding fragment of clazakizumab, or the polypeptide.

8. 3. The method of claim 1 or 2, wherein the solid organ is a kidney.

9. 3. The method of claim 1 or 2, wherein the solid organ is one or more of the heart, liver, lung, pancreas, and intestine.

10. 3. The method of claim 1 or 2, wherein the clazakizumab, IL-6-binding fragment of clazakizumab, or polypeptide is administered subcutaneously or intravenously.

11. Clazakizumab, an IL-6-binding fragment of clzakizumab, or a polypeptide is administered at a dose of about 0.1-1 mg / month, 1-5 mg / month, 5-10 mg / month, 10-20 mg / month, 20-30 mg / month, or 30-40 mg / month for at least 1 month and up to 18 months. The method according to claim 1 or 2, wherein the average dose is administered subcutaneously.

12. 3. The method of claim 1 or 2, wherein multiple doses of clazakizumab, an IL-6 binding fragment of clazakizumab, or a polypeptide are administered at intervals of about once a month for 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months.

13. 3. The method of claim 1 or 2, wherein the clazakizumab, IL-6 binding fragment of clazakizumab, or polypeptide is administered subcutaneously at an average dose of about 10-30 mg / administration 1, 2, 3, 4, 5, or 6 times prior to solid organ transplantation and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 times after solid organ transplantation.

14. The method of claim 1 or 2, wherein the subject is a human.

15. 3. The method of claim 1 or 2, further comprising administering to the subject one or more anti-infective agents.

16. 16. The method of claim 15, wherein the one or more anti-infective agents are administered in conjunction with or after the solid organ transplant.

17. 15. The method of claim 14, wherein the anti-infective agent comprises ganciclovir, valganciclovir, fluconazole, trimethoprim, sulfamethoxazole, or a combination thereof.

18. 3. The method of claim 1 or 2, further comprising administering a standard of care treatment comprising intravenous immunoglobulin (IVIG) administration, rituximab administration, plasma exchange, or a combination thereof; an anti-infective agent; or a combination of a standard of care treatment and an anti-infective agent.

19. The method of claim 1 or 2, further comprising selecting human subjects with a calculated panel reactive antibody (cPRA) of 50% or more, or performing a panel reactive antibody assay and determining human subjects with a cPRA of 50% or more.

20. 3. The method of claim 1 or 2, wherein following a solid organ transplant, the subject shows no detectable evidence of the development of antibody-mediated rejection of the solid organ transplant, no detectable evidence of the development of a viral infection, or both.

21. 3. The method of claim 1 or 2, further comprising administering antibody induction therapy including alemtuzumab, antithymocyte globulin, or both after solid organ transplantation; administering immunosuppressive therapy including tacrolimus, mycophenolate mofetil, prednisone, or a combination thereof; or administering antibody induction therapy and immunosuppressive therapy.

22. 3. The method of claim 1 or 2, wherein the subject in need of a solid organ transplant is receiving a solid organ transplant or the subject has received a solid organ transplant, and the method further comprises performing one or more immune monitoring on the subject, the immune monitoring comprising assaying a blood sample from the subject to quantify levels of markers including CRP, Treg, Tfh, Th17, B cells, IL-6, plasma cells, plasmablast IgG, or combinations thereof.

23. Based on one or more markers that are at lower levels compared to baseline measurements obtained at or before solid organ transplantation, or based on baseline measurements obtained from previous immune monitoring.

23. The method of claim 22, wherein further administration of clazakizumab, an IL-6-binding fragment of clazakizumab, or the polypeptide is discontinued or limited to an additional six months or less if immune monitoring indicates improvement based on one or more levels of the marker being lower compared to baseline measurements or results from previous immune monitoring; and administering one or more doses of clazakizumab, an IL-6-binding fragment of clazakizumab, or the polypeptide if immune monitoring indicates poor performance based on similar or higher levels of the marker compared to baseline measurements or results from previous immune monitoring.

24. 3. The method of claim 1 or 2, wherein the subject in need of a solid organ transplant is undergoing a solid organ transplant or the subject has undergone a solid organ transplant, and the method further comprises measuring the amount of glomerular filtration rate, DSA, or both after the solid organ transplant.

25. 25. The method of claim 24, wherein further administration of clazakizumab, an IL-6 binding fragment of clazakizumab, or a polypeptide is discontinued or limited to an additional 6 months or less if the amount of glomerular filtration rate, DSA, or both is similar or lower compared to baseline levels measured prior to or at the time of solid organ transplant; and one or more doses of clazakizumab, an IL-6 binding fragment of clazakizumab, or a polypeptide are administered if the amount of glomerular filtration rate, DSA, or both is higher compared to baseline levels.

Citation Information

Cited By

  • Composite magnetic material, magnetic wedge, core, and rotating electrical machine

    CN121709363A